SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 261 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.01 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,156,112 | -62.9% | 78,205 | -59.6% | 0.00% | -66.7% |
| Q2 2023 | $5,815,858 | +204323.8% | 193,475 | +146.3% | 0.00% | +50.0% |
| Q1 2023 | $2,845 | -82.4% | 78,537 | -82.7% | 0.00% | -77.8% |
| Q4 2022 | $16,174 | -99.8% | 453,448 | +85.7% | 0.01% | +125.0% |
| Q2 2022 | $7,063,000 | +164.2% | 244,223 | +166.4% | 0.00% | +300.0% |
| Q4 2021 | $2,673,000 | -76.6% | 91,662 | -78.6% | 0.00% | -85.7% |
| Q3 2021 | $11,402,000 | +253.2% | 427,524 | +307.8% | 0.01% | +250.0% |
| Q2 2021 | $3,228,000 | +500.0% | 104,845 | +410.6% | 0.00% | – |
| Q1 2021 | $538,000 | +141.3% | 20,532 | +131.8% | 0.00% | – |
| Q4 2020 | $223,000 | -0.9% | 8,859 | -17.9% | 0.00% | – |
| Q3 2020 | $225,000 | -68.6% | 10,789 | -64.3% | 0.00% | -100.0% |
| Q2 2020 | $717,000 | -96.5% | 30,195 | -96.5% | 0.00% | -96.0% |
| Q4 2019 | $20,377,000 | +49.0% | 859,076 | +72.7% | 0.02% | +13.6% |
| Q3 2019 | $13,672,000 | +25.1% | 497,551 | +50.7% | 0.02% | +37.5% |
| Q2 2019 | $10,925,000 | -32.1% | 330,173 | -28.1% | 0.02% | -33.3% |
| Q1 2019 | $16,094,000 | +73.0% | 459,308 | +64.0% | 0.02% | +60.0% |
| Q4 2018 | $9,302,000 | -20.3% | 280,003 | +20.8% | 0.02% | +7.1% |
| Q3 2018 | $11,669,000 | +20.5% | 231,748 | +43.2% | 0.01% | +7.7% |
| Q2 2018 | $9,685,000 | -50.0% | 161,817 | -61.7% | 0.01% | -50.0% |
| Q1 2018 | $19,370,000 | -8.5% | 422,928 | -20.4% | 0.03% | -10.3% |
| Q4 2017 | $21,176,000 | -1.0% | 531,397 | -0.6% | 0.03% | -12.1% |
| Q3 2017 | $21,380,000 | +5709.8% | 534,509 | +6162.6% | 0.03% | +3200.0% |
| Q2 2017 | $368,000 | -97.9% | 8,535 | -98.5% | 0.00% | -97.0% |
| Q1 2017 | $17,933,000 | +147.1% | 572,938 | +99.3% | 0.03% | +120.0% |
| Q4 2016 | $7,258,000 | -6.3% | 287,431 | -8.3% | 0.02% | +15.4% |
| Q3 2016 | $7,749,000 | -30.5% | 313,358 | -42.8% | 0.01% | -50.0% |
| Q2 2016 | $11,154,000 | +381.0% | 547,589 | +260.2% | 0.03% | +333.3% |
| Q1 2016 | $2,319,000 | -18.5% | 152,041 | -28.2% | 0.01% | 0.0% |
| Q4 2015 | $2,845,000 | +85.6% | 211,659 | +134.4% | 0.01% | +100.0% |
| Q2 2015 | $1,533,000 | -70.1% | 90,291 | -78.7% | 0.00% | -70.0% |
| Q1 2015 | $5,125,000 | +10.3% | 423,938 | -24.3% | 0.01% | 0.0% |
| Q4 2014 | $4,648,000 | +96.3% | 560,058 | +105.5% | 0.01% | +66.7% |
| Q3 2014 | $2,368,000 | +602.7% | 272,545 | +623.7% | 0.01% | +500.0% |
| Q1 2014 | $337,000 | -50.7% | 37,659 | -58.5% | 0.00% | -50.0% |
| Q4 2013 | $684,000 | -48.5% | 90,708 | -49.9% | 0.00% | -50.0% |
| Q3 2013 | $1,328,000 | +122.4% | 181,221 | +95.1% | 0.00% | +100.0% |
| Q2 2013 | $597,000 | – | 92,868 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 426,500 | $11,754,340 | 3.96% |
| ASHFORD CAPITAL MANAGEMENT INC | 916,747 | $25,274,715 | 3.72% |
| ARMISTICE CAPITAL, LLC | 5,092,000 | $140,386,440 | 2.15% |
| S&T BANK/PA | 215,578 | $5,943 | 1.15% |
| Aristotle Capital Boston, LLC | 1,187,981 | $32,752,634 | 1.06% |
| RICE HALL JAMES & ASSOCIATES, LLC | 544,468 | $15,010,983 | 0.95% |
| Tributary Capital Management, LLC | 352,429 | $9,716,468 | 0.92% |
| Bridge City Capital, LLC | 65,297 | $1,800,238 | 0.91% |
| Integral Health Asset Management, LLC | 220,000 | $6,065,400 | 0.84% |
| Retirement Planning Co of New England, Inc. | 51,608 | $1,422,833 | 0.79% |